MA55090A - Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs - Google Patents
Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifsInfo
- Publication number
- MA55090A MA55090A MA055090A MA55090A MA55090A MA 55090 A MA55090 A MA 55090A MA 055090 A MA055090 A MA 055090A MA 55090 A MA55090 A MA 55090A MA 55090 A MA55090 A MA 55090A
- Authority
- MA
- Morocco
- Prior art keywords
- prophylactic
- truncated
- diagnostic
- binding
- medicinal product
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019036119 | 2019-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55090A true MA55090A (fr) | 2022-01-05 |
Family
ID=72239809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055090A MA55090A (fr) | 2019-02-28 | 2020-02-28 | Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3932952A4 (fr) |
| JP (1) | JP7527589B2 (fr) |
| KR (1) | KR20210134705A (fr) |
| CN (1) | CN113508140B (fr) |
| AU (1) | AU2020227989A1 (fr) |
| BR (1) | BR112021016619A2 (fr) |
| CA (1) | CA3130909A1 (fr) |
| IL (1) | IL285267A (fr) |
| MA (1) | MA55090A (fr) |
| MX (1) | MX2021010404A (fr) |
| SG (1) | SG11202108494YA (fr) |
| WO (1) | WO2020175689A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116322763A (zh) * | 2020-08-27 | 2023-06-23 | 学校法人顺天堂 | 抗切断型突变calr-cd3双特异性抗体及医药组合物 |
| CN114395037B (zh) * | 2021-11-03 | 2023-01-17 | 深圳市人民医院 | 靶向钙网蛋白的纳米抗体及其应用 |
| GEAP202416555A (en) | 2021-12-08 | 2024-10-28 | Incyte Corp | Anti-mutant calreticulin (calr) antibodies and uses thereof |
| AU2022416990A1 (en) * | 2021-12-13 | 2024-07-18 | Adelaide university | Antibodies to mutant calreticulin and uses thereof |
| TW202342097A (zh) | 2022-02-25 | 2023-11-01 | 學校法人順天堂 | 抗突變calr抗體與其他藥劑組合而成之醫藥 |
| CN117003866B (zh) * | 2023-08-23 | 2025-06-06 | 复旦大学附属华山医院 | 一种抗calr突变蛋白抗体、制备方法及检测试剂盒 |
| WO2026013015A1 (fr) * | 2024-07-09 | 2026-01-15 | Merus N.V. | Fractions de liaison multispécifiques comprenant des domaines de liaison à calr et cd3 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1996033735A1 (fr) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives d'une xenosouris immunisee |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (fr) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Animaux transgeniques non humains capables de produire des anticorps heterologues |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| EP0605522B1 (fr) | 1991-09-23 | 1999-06-23 | Medical Research Council | Méthodes de production d'anticorps humanisés |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| CA2131151A1 (fr) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methodes de production d'elements formant des paires specifiques de liaison |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (fr) | 1993-12-03 | 1995-06-08 | Medical Research Council | Proteines et peptides de liaison recombines |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| WO1996034096A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
| MX348980B (es) * | 2013-09-16 | 2017-07-05 | Cemm-Forschungszentrum Für Molekulare Medizin Gmbh | Calreticulina mutante para la diagnosis de malignidades mieloides. |
| EP3029060A1 (fr) * | 2014-12-01 | 2016-06-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Plantes supérieures génétiquement modifiées avec photosynthèse améliorée et/ou production de biomasse, procédés et utilisations associées |
| WO2016087514A1 (fr) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anticorps anticalréticuline mutante et leur utilisation dans le diagnostic et la thérapie de tumeurs malignes myéloïdes |
| JP2017062127A (ja) | 2015-09-24 | 2017-03-30 | 学校法人順天堂 | 骨髄増殖性腫瘍予防又は治療薬のスクリーニング方法 |
-
2020
- 2020-02-28 SG SG11202108494YA patent/SG11202108494YA/en unknown
- 2020-02-28 MA MA055090A patent/MA55090A/fr unknown
- 2020-02-28 AU AU2020227989A patent/AU2020227989A1/en active Pending
- 2020-02-28 EP EP20763555.8A patent/EP3932952A4/fr active Pending
- 2020-02-28 BR BR112021016619A patent/BR112021016619A2/pt unknown
- 2020-02-28 WO PCT/JP2020/008434 patent/WO2020175689A1/fr not_active Ceased
- 2020-02-28 MX MX2021010404A patent/MX2021010404A/es unknown
- 2020-02-28 CN CN202080017462.8A patent/CN113508140B/zh active Active
- 2020-02-28 JP JP2021502656A patent/JP7527589B2/ja active Active
- 2020-02-28 CA CA3130909A patent/CA3130909A1/fr active Pending
- 2020-02-28 KR KR1020217031154A patent/KR20210134705A/ko active Pending
-
2021
- 2021-08-01 IL IL285267A patent/IL285267A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3932952A1 (fr) | 2022-01-05 |
| SG11202108494YA (en) | 2021-09-29 |
| MX2021010404A (es) | 2021-09-14 |
| US20220098290A1 (en) | 2022-03-31 |
| KR20210134705A (ko) | 2021-11-10 |
| IL285267A (en) | 2021-09-30 |
| EP3932952A4 (fr) | 2022-11-30 |
| CN113508140B (zh) | 2024-11-19 |
| AU2020227989A1 (en) | 2021-09-09 |
| BR112021016619A2 (pt) | 2021-11-03 |
| WO2020175689A1 (fr) | 2020-09-03 |
| CA3130909A1 (fr) | 2020-09-03 |
| JPWO2020175689A1 (fr) | 2020-09-03 |
| JP7527589B2 (ja) | 2024-08-05 |
| CN113508140A (zh) | 2021-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55090A (fr) | Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| EP3612566A4 (fr) | Anticorps antagonistes de cd 14 pour le traitement de maladies neurodégénératives | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| EP3645742A4 (fr) | Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation | |
| MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| EP2860188A4 (fr) | Polypeptides et anticorps pour le traitement d'une infection par le vbh et maladies associées | |
| EP3645040A4 (fr) | Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers | |
| EP3645039A4 (fr) | Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose | |
| MA33989B1 (fr) | Formulation d'anticorps et régimes thérapeutiques | |
| MA44763A (fr) | Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang | |
| EP2652506A4 (fr) | Utilisation d'anticorps anti-cxcl16 et anti-cxcr6 pour le traitement ou la détection du cancer | |
| EP3712170A4 (fr) | Anticorps cd96, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée | |
| MA54089A (fr) | Anticorps anti-pd-1 humain et procédés d'utilisation associés | |
| LT2013015A (lt) | Farmacinės kompozicijos | |
| EP3883602A4 (fr) | Antigènes peptidiques de la protéine tau et anticorps se liant à ceux-ci pour le traitement des tauopathies | |
| EP3927729A4 (fr) | Formulation d'anticorps thérapeutique | |
| EP2524693A4 (fr) | Produit pharmaceutique destiné au traitement prophylactique ou thérapeutique de troubles accompagnés d'une angiogenèse oculaire et/ou d'une perméabilité vasculaire oculaire supérieure à la normale | |
| EP3502248A4 (fr) | Anticorps dirigés contre hmgb1 et composition les comprenant pour le traitement ou la prévention de la maladie d'alzheimer | |
| EP3528820A4 (fr) | Nouvelles formulations liposomales pegylées d'apeline pour le traitement de maladies liées au système cardiovasculaire | |
| EP3877418A4 (fr) | Schéma posologique d'anticorps anti-tigit pour le traitement du cancer | |
| MA52485A (fr) | Combinaisons de variants d'anticorps et utilisations associées | |
| EP4079761A4 (fr) | Conjugué anticorps anti-cea-analogue d'exatécan et utilisation pharmaceutique de celui-ci | |
| EP3326640A4 (fr) | Application de la protéine de moule à action adhésive pour le traitement et la prévention de maladies associées à la mélanine | |
| MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc |